-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bria-IMT in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bria-IMT in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bria-IMT in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bria-IMT in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bria-IMT in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bria-IMT in Triple-Negative Breast Cancer (TNBC) Drug Details: Bria-IMT (BriaVax) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bria-IMT in Metastatic Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bria-IMT in Metastatic Breast Cancer Drug Details: Bria-IMT (BriaVax) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Molgramostim in Lung Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Molgramostim in Lung Disease Drug Details: Molgramostim (Molgradex) is under development for the treatment of...
-
Product Insights
New![]()
Bang Bo Combined Cycle Power Plant
Bang Bo Combined Cycle Power Plant is a thermal project located in Samut Prakan, Thailand. The project is owned by GMS Power Public Co Ltd; SG Bang Bo Power Holding Co Ltd; Tokyo Gas Asia Pte Ltd and was developed by GMS Power Public Co Ltd. The project came online in 2003. Empower your strategies with our Bang Bo Combined Cycle Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VBI-1901 in Recurrent Glioblastoma Multiforme (GBM)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. VBI-1901 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: VBI-1901 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Namilumab in Pulmonary Sarcoidosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Namilumab in Pulmonary SarcoidosisDrug Details:Namilumab (MT203, IZN-101, AMG203) is under development for the treatment of ankylosing...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MS-20 in Ulcerative Colitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MS-20 in Ulcerative Colitis Drug Details: MS-20 is under development for the treatment of non-small cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma (cSCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma (cSCC) Drug Details: RP-1 is under development for...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.